Evestra Snags DoD Grant For Experimental Breast Cancer Drug Research

By David Holley, Xconomy San Antonio—A small Texas biotech that develops women’s health ...

Promising Treatment for Ebola Virus to be Tested at Texas Biomed

Ricardo Carrion, Jr., Ph.D. During the West African Ebola outbreak that began in 2013, an experimental ...

GenSpera enrolls first patient in cancer trial
January 28, 2010

GenSpera Inc. has reached a milestone in the development of its investigational cancer drug.

In a phase 1 clinical study, doctors at the University of Wisconsin Carbone Cancer Center in Madison treated the first patient with GenSpera’s cancer chemotherapeutic agent G-202.

The phase 1 clinical study is designed to treat up to 30 patients with cancers that have progressed even after treatment with other anti-cancer therapies. The study will determine the safety, tolerability and effect the drug has on the human body. Researchers will also study how effective the drug is in treating solid tumors.

G-202 is designed to target the blood vessels in solid tumors in order to destroy the tumor’s blood supply.

San Antonio-based GenSpera is a development stage oncology company.

Stay informed. Subscribe to BioMed SA news alerts.